vs
美国航空集团（AAL）与吉利德科学（GILD）财务数据对比。点击上方公司名可切换其他公司
美国航空集团的季度营收约是吉利德科学的1.8倍（$14.0B vs $7.9B），吉利德科学净利率更高（27.5% vs 0.7%，领先26.8%），吉利德科学同比增速更快（4.7% vs 2.5%），吉利德科学自由现金流更多（$3.1B vs $-1.9B），过去两年吉利德科学的营收复合增速更高（8.9% vs 5.5%）
美国航空集团是美国头部航司，总部坐落于得克萨斯州沃斯堡的达拉斯-沃斯堡都会区，按客运量、日航班量计算为全球最大航司。集团旗下连同区域子公司及以American Eagle品牌运营的合作航司，每日运营近6800个航班，覆盖48个国家近350个目的地，拥有完善的国内外航线网络。
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
AAL vs GILD — 直观对比
营收规模更大
AAL
是对方的1.8倍
$7.9B
营收增速更快
GILD
高出2.2%
2.5%
净利率更高
GILD
高出26.8%
0.7%
自由现金流更多
GILD
多$5.0B
$-1.9B
两年增速更快
GILD
近两年复合增速
5.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.0B | $7.9B |
| 净利润 | $99.0M | $2.2B |
| 毛利率 | — | 79.5% |
| 营业利润率 | 3.2% | 25.0% |
| 净利率 | 0.7% | 27.5% |
| 营收同比 | 2.5% | 4.7% |
| 净利润同比 | -83.2% | 22.4% |
| 每股收益（稀释后） | $0.15 | $1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AALGILD
| Q4 25 | $14.0B | $7.9B | ||
| Q3 25 | $13.7B | $7.8B | ||
| Q2 25 | $14.4B | $7.1B | ||
| Q1 25 | $12.6B | $6.7B | ||
| Q4 24 | $13.7B | $7.6B | ||
| Q3 24 | $13.6B | $7.5B | ||
| Q2 24 | $14.3B | $7.0B | ||
| Q1 24 | $12.6B | $6.7B |
净利润AALGILD
| Q4 25 | $99.0M | $2.2B | ||
| Q3 25 | $-114.0M | $3.1B | ||
| Q2 25 | $599.0M | $2.0B | ||
| Q1 25 | $-473.0M | $1.3B | ||
| Q4 24 | $590.0M | $1.8B | ||
| Q3 24 | $-149.0M | $1.3B | ||
| Q2 24 | $717.0M | $1.6B | ||
| Q1 24 | $-312.0M | $-4.2B |
毛利率AALGILD
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 79.8% | ||
| Q2 25 | — | 78.8% | ||
| Q1 25 | — | 76.9% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | — | 79.1% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 76.8% |
营业利润率AALGILD
| Q4 25 | 3.2% | 25.0% | ||
| Q3 25 | 1.1% | 42.8% | ||
| Q2 25 | 7.9% | 34.9% | ||
| Q1 25 | -2.2% | 33.6% | ||
| Q4 24 | 8.3% | 32.4% | ||
| Q3 24 | 0.7% | 11.8% | ||
| Q2 24 | 9.7% | 38.0% | ||
| Q1 24 | 0.1% | -64.6% |
净利率AALGILD
| Q4 25 | 0.7% | 27.5% | ||
| Q3 25 | -0.8% | 39.3% | ||
| Q2 25 | 4.2% | 27.7% | ||
| Q1 25 | -3.8% | 19.7% | ||
| Q4 24 | 4.3% | 23.6% | ||
| Q3 24 | -1.1% | 16.6% | ||
| Q2 24 | 5.0% | 23.2% | ||
| Q1 24 | -2.5% | -62.4% |
每股收益（稀释后）AALGILD
| Q4 25 | $0.15 | $1.75 | ||
| Q3 25 | $-0.17 | $2.43 | ||
| Q2 25 | $0.91 | $1.56 | ||
| Q1 25 | $-0.72 | $1.04 | ||
| Q4 24 | $0.94 | $1.43 | ||
| Q3 24 | $-0.23 | $1.00 | ||
| Q2 24 | $1.01 | $1.29 | ||
| Q1 24 | $-0.48 | $-3.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $68.0M |
| 总债务越低越好 | $25.3B | $24.9B |
| 股东权益账面价值 | $-3.7B | $22.7B |
| 总资产 | $61.8B | $59.0B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资AALGILD
| Q4 25 | — | $68.0M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | — | $69.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
总债务AALGILD
| Q4 25 | $25.3B | $24.9B | ||
| Q3 25 | $25.1B | $24.9B | ||
| Q2 25 | $25.3B | $24.9B | ||
| Q1 25 | $24.7B | $25.0B | ||
| Q4 24 | $25.2B | $26.7B | ||
| Q3 24 | $26.3B | $23.2B | ||
| Q2 24 | $27.6B | $23.3B | ||
| Q1 24 | $28.2B | $25.2B |
股东权益AALGILD
| Q4 25 | $-3.7B | $22.7B | ||
| Q3 25 | $-4.0B | $21.5B | ||
| Q2 25 | $-3.9B | $19.7B | ||
| Q1 25 | $-4.5B | $19.2B | ||
| Q4 24 | $-4.0B | $19.3B | ||
| Q3 24 | $-4.9B | $18.5B | ||
| Q2 24 | $-4.7B | $18.3B | ||
| Q1 24 | $-5.5B | $17.5B |
总资产AALGILD
| Q4 25 | $61.8B | $59.0B | ||
| Q3 25 | $62.1B | $58.5B | ||
| Q2 25 | $63.7B | $55.7B | ||
| Q1 25 | $62.6B | $56.4B | ||
| Q4 24 | $61.8B | $59.0B | ||
| Q3 24 | $63.5B | $54.5B | ||
| Q2 24 | $64.1B | $53.6B | ||
| Q1 24 | $64.4B | $56.3B |
负债/权益比AALGILD
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.30× | ||
| Q4 24 | — | 1.38× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-274.0M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $-1.9B | $3.1B |
| 自由现金流率自由现金流/营收 | -13.6% | 39.4% |
| 资本支出强度资本支出/营收 | 11.6% | 2.6% |
| 现金转化率经营现金流/净利润 | -2.77× | 1.52× |
| 过去12个月自由现金流最近4个季度 | $-680.0M | $9.5B |
8季度趋势，按日历期对齐
经营现金流AALGILD
| Q4 25 | $-274.0M | $3.3B | ||
| Q3 25 | $-46.0M | $4.1B | ||
| Q2 25 | $963.0M | $827.0M | ||
| Q1 25 | $2.5B | $1.8B | ||
| Q4 24 | $398.0M | $3.0B | ||
| Q3 24 | $277.0M | $4.3B | ||
| Q2 24 | $1.1B | $1.3B | ||
| Q1 24 | $2.2B | $2.2B |
自由现金流AALGILD
| Q4 25 | $-1.9B | $3.1B | ||
| Q3 25 | $-872.0M | $4.0B | ||
| Q2 25 | $464.0M | $720.0M | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $-342.0M | $2.8B | ||
| Q3 24 | $-191.0M | $4.2B | ||
| Q2 24 | $477.0M | $1.2B | ||
| Q1 24 | $1.4B | $2.1B |
自由现金流率AALGILD
| Q4 25 | -13.6% | 39.4% | ||
| Q3 25 | -6.4% | 51.0% | ||
| Q2 25 | 3.2% | 10.2% | ||
| Q1 25 | 13.0% | 24.8% | ||
| Q4 24 | -2.5% | 37.4% | ||
| Q3 24 | -1.4% | 55.2% | ||
| Q2 24 | 3.3% | 17.2% | ||
| Q1 24 | 10.8% | 31.6% |
资本支出强度AALGILD
| Q4 25 | 11.6% | 2.6% | ||
| Q3 25 | 6.0% | 1.9% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 6.6% | 1.6% | ||
| Q4 24 | 5.4% | 1.9% | ||
| Q3 24 | 3.4% | 1.9% | ||
| Q2 24 | 4.5% | 1.9% | ||
| Q1 24 | 6.6% | 1.6% |
现金转化率AALGILD
| Q4 25 | -2.77× | 1.52× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | 1.61× | 0.42× | ||
| Q1 25 | — | 1.34× | ||
| Q4 24 | 0.67× | 1.67× | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | 1.57× | 0.82× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAL
| Passenger Travel | $11.6B | 83% |
| Loyalty Program Travel Redemptions | $1.1B | 8% |
| Loyalty Program Marketing Services | $945.0M | 7% |
| Cargo And Freight | $227.0M | 2% |
| Other Revenue | $169.0M | 1% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
